Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01480700
Other study ID # 2011-A00364-37
Secondary ID
Status Completed
Phase N/A
First received September 13, 2011
Last updated August 2, 2013
Start date October 2011
Est. completion date February 2013

Study information

Verified date August 2013
Source Institut Pasteur de Lille
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)France: Committee for the Protection of Personnes
Study type Interventional

Clinical Trial Summary

This study is to determine the impact of the consumption of eggs rich in lutein/zeaxanthin from lucerne protein concentrate and DHA from microalgae on the plasma levels of these compounds but also on the macular pigment optical density, whose elevation may be beneficial in the prevention of Age-related Macular Degeneration (AMD).


Recruitment information / eligibility

Status Completed
Enrollment 99
Est. completion date February 2013
Est. primary completion date February 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- healthy subjects (male or female),

- 18 to 55 years

- Having signed the consent form,

- Susceptible to accept the stresses generated by the study,

- Insured.

Exclusion Criteria:

- Corrected Visual Acuity <8/10th,

- History of cardiovascular disease, specifically coronary heart disease,

- Characterized dyslipidemia

* Total cholesterol ³ 2.50 g / L, and / or triglycerides ³ 2.00 g / L

- Lipid-lowering treatment,

- Current smoking or person who stopped smoking less than 6 months

- Cataract or cataract surgery,

- Diabetes

- Body Mass Index (BMI)> 30 kg/m2,

- Taking food supplements in the 3 months preceding the start of the study (carotenoids, omega-3 fatty acids, phytosterols),

- Regular consumption in the three months preceding the start of the study products with added phytosterols.

- Regular consumption of high fatty fish or shellfish rich in omega-3 (4x a week or more): salmon, sardines, mackerel, herring, trout, tuna, red mullet, sea bass, bream, farmed turbot, mussels, squid / squid, anchovies.

- Allergy to eggs

- Dieting

- Difference significant weight over the last 3 months (> 3 kg)

- Inability to understand or adhere to the protocol

- Persons deprived of liberty

- People in a position to judicial protection

- Pregnant Women.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
Nutritional study
subjects consume 2 eggs per day during 4 months

Locations

Country Name City State
France Institut Pasteur de Lille Lille

Sponsors (3)

Lead Sponsor Collaborator
Institut Pasteur de Lille Roquette Freres, Sanders

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary change from baseline in optical density of macular pigment after 4 months of eggs consumption optical density of macular pigment was measured with a Heidelberg Retinal Angiograph (HRA)specially modify for the measure of the pigment. before the eggs consumption and four months afterwards Yes
Secondary change from baseline in lutein and zeaxanthin in plasma and lipoproteins after 4 months of egg consumption lutein and zeaxanthin were measured by HPLC before the eggs consumption and four months afterwards Yes
Secondary change from baseline in fatty acids in plasma and lipoproteins after 4 months of egg consumption Fatty acids were measured by Gas Chromatography. before the eggs consumption and four months afterwards Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05984927 - NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT05536297 - Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy Phase 3
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Completed NCT04005352 - Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Phase 3
Withdrawn NCT02873351 - A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration Phase 2
Active, not recruiting NCT02802657 - Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration Phase 4
Not yet recruiting NCT02864472 - Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose Phase 4
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT01445548 - Sirolimus for Advanced Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT02035722 - Intravitreal Injections-related Anxiety Phase 2/Phase 3
Completed NCT01175395 - 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Recruiting NCT01048476 - Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT01174407 - Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration N/A
Terminated NCT00712491 - Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00345176 - Age-Related Eye Disease Study 2 (AREDS2) Phase 3
Completed NCT02140151 - Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration Phase 1/Phase 2
Completed NCT02555306 - A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration Phase 1/Phase 2
Recruiting NCT04796545 - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration N/A
Completed NCT03166202 - Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
Completed NCT01397409 - Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) Phase 2